Not a competition and most probably a complement ,
Post# of 148327
(Total Views: 127)
Posted On: 03/12/2019 8:13:46 AM
Not a competition and most probably a complement , more for checkpoint inhibitors.
At one time Dr NP said that they consider some study with Keytruda , when this will happen then we will see exactly how much less side effects Keytruda will produce.
The most serious side effects checkpoint inhibitors are producing is autoimmune reaction , when our immune system attack our organs , not only cancer tumors, and we know that Leronlimab is preventing many of this . We know it is stopping GvHD , we have very good results with MS ...
I spoke about this with Dr NP , to use Leronlimab preventably with check point inhibitors even with CCR5 negative cancers , he told me that they , ( our comp ) spoke about this , but for now they want to concentrate on HIV , cancer and GvHD.
At one time Dr NP said that they consider some study with Keytruda , when this will happen then we will see exactly how much less side effects Keytruda will produce.
The most serious side effects checkpoint inhibitors are producing is autoimmune reaction , when our immune system attack our organs , not only cancer tumors, and we know that Leronlimab is preventing many of this . We know it is stopping GvHD , we have very good results with MS ...
I spoke about this with Dr NP , to use Leronlimab preventably with check point inhibitors even with CCR5 negative cancers , he told me that they , ( our comp ) spoke about this , but for now they want to concentrate on HIV , cancer and GvHD.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼